iMDx Expands GraftAssure Utilization as First Patient Samples Arrive for GALACTIC Registry Study
Key Highlights
- ➤GALACTIC registry enrolls first patients in planned 5,000-participant multi-center study
- ➤GraftAssureDx in-vitro diagnostic kit remains under FDA review
- ➤GALACTIC targets positive predictive value above 80% for biopsy-confirmed rejection
- ➤CM-Score previously demonstrated 81% positive predictive value and 91% negative predictive value
- ➤GraftAssureCore reimbursed by CMS MolDX at $2,753 per result
Expert Statements
Suphamai (Michael) Bunnapradist, MD, MS, UCLA Medical Center
“Through this registry we will be able to monitor our patients’ transplanted kidney health, initially with a send-out test and ultimately through in-house testing.”
Suphamai (Michael) Bunnapradist, MD, MS, UCLA Medical Center
“It is also very exciting to be the center that enrolled the first patient into this national registry.”
Josh Riggs, CEO of Insight Molecular Diagnostics
“We are excited to enroll our first patients in the GALACTIC registry study, the goal of which is to gather performance metrics on GraftAssure to guide biopsy and treatment decisions and congratulations to the UCLA team on enrolling the first participants.”
Josh Riggs, CEO of Insight Molecular Diagnostics
“UCLA played a foundational role in validating donor-derived cell-free DNA for transplant monitoring, and we are pleased to have them help answer an important clinical question: ‘Can GraftAssure better identify patients whose biopsies will confirm rejection?’”
Josh Riggs, CEO of Insight Molecular Diagnostics
“GALACTIC aims to demonstrate a positive predictive value above 80%, compared with roughly 50% for current assays.”
Josh Riggs, CEO of Insight Molecular Diagnostics
“Enrollment also allows more transplant teams to gain firsthand experience with GraftAssure.”
Josh Riggs, CEO of Insight Molecular Diagnostics
“We expect that the data from this registry is what payers and clinicians will look to for real-world evidence, and that it will support payer coverage decisions down the line for the family of products using GraftAssure technology.”
* Patient samples arrive in Tennessee from UCLA Medical Center, officially kicking off 5,000-participant, multi-center novel registry first announced September 2025 * Registry program is designed to be incremental, complementary, and symbiotic to iMDx “kitted strategy” and allow clinical community to gain experience using GraftAssure testing technology * Study involvement expected to expand access to GraftAssure technology ahead of potential FDA authorization of a kitted form of the clinical assay, currently under review NASHVILLE, Tenn., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that the first several patients have been enrolled in its GALACTIC (GraftAssure Lowering Allograft rejeCTIon by Combination) registry study, a prospective, multi-center validation study evaluating GraftAssure(TM), the company's molecular test for monitoring rejection in kidney transplant recipients.
Get started
Create a free account to read the full story.
